Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products internationally. They offer prescription medicines in areas like cardiovascular, immunology, oncology, ophthalmology, and hematology. The company has agreements with Alnylam Pharmaceuticals and Dawn Health to develop and commercialize inclisiran and Ekiva respectively.
Overview
Strengths
- Current Price to Earnings Ratio (19.22) is lower than the sector mean (81.73).
- The company has low debt. Net Debt to EBITDA Ratio is 0.86 and it is lower than the sector mean.
- The company has high returns. ROIC (23.97%) is higher than the sector mean (16.32%).
- EV/EBIT (16.90) is lower than the sector mean.
- Price to free cash flow (16.62) is lower than the sector mean.
- Strong EBITDA Margin of 41.53%.
Weaknesses
- No significant weaknesses identified based on the analyzed metrics.
Key Financial Data
| Indicator | Value |
|---|
| PER | 19.4 |
| EV/EBITDA | 11.9 |
| Price/Free Cash Flow' | 16.8 |
| ROIC | 24.0% |
| Net Debt/EBITDA | 0.9 |